{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastrointestinal+Carcinoma&page=61", "query": { "condition": "Gastrointestinal Carcinoma", "page": 61 }, "page_size": 10 }, "pagination": { "page": 61, "page_size": 10, "total_count": 2730, "total_pages": 273, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastrointestinal+Carcinoma&page=62&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastrointestinal+Carcinoma&page=60&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-18T12:17:18.313Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01869725", "title": "Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adult Medulloblastoma", "Childhood Medulloblastoma", "Neuroblastoma", "Neuroendocrine Tumor", "Somatostatinoma" ], "interventions": [ { "name": "gallium Ga 68-edotreotide", "type": "DRUG" }, { "name": "positron emission tomography/computed tomography", "type": "PROCEDURE" }, { "name": "indium In 111 pentetreotide", "type": "RADIATION" }, { "name": "computed tomography", "type": "PROCEDURE" }, { "name": "contrast-enhanced magnetic resonance imaging", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Sue O'Dorisio", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 68, "start_date": "2013-04-01", "completion_date": "2018-12-26", "has_results": true, "last_update_posted_date": "2021-09-22", "last_synced_at": "2026-10-18T12:17:18.313Z", "location_count": 1, "location_summary": "Iowa City, Iowa", "locations": [ { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT01869725" }, { "nct_id": "NCT06750185", "title": "Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "BNT317 DL1", "type": "BIOLOGICAL" }, { "name": "BNT317 DL2", "type": "BIOLOGICAL" }, { "name": "BNT317 DL3", "type": "BIOLOGICAL" }, { "name": "BNT317 DL4", "type": "BIOLOGICAL" }, { "name": "BNT317 DL5", "type": "BIOLOGICAL" }, { "name": "BNT317 DL6", "type": "BIOLOGICAL" }, { "name": "BNT317 selected DLA", "type": "BIOLOGICAL" }, { "name": "BNT317 selected DLB", "type": "BIOLOGICAL" }, { "name": "SoC chemotherapy 1", "type": "DRUG" }, { "name": "SoC chemotherapy 2", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "BioNTech SE", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 248, "start_date": "2025-01-13", "completion_date": "2031-04", "has_results": false, "last_update_posted_date": "2026-09-09", "last_synced_at": "2026-10-18T12:17:18.313Z", "location_count": 7, "location_summary": "Louisville, Kentucky • Grand Rapids, Michigan • Huntersville, North Carolina + 4 more", "locations": [ { "city": "Louisville", "state": "Kentucky" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Huntersville", "state": "North Carolina" }, { "city": "East Providence", "state": "Rhode Island" }, { "city": "Charleston", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06750185" }, { "nct_id": "NCT00183885", "title": "A Phase II Study of Intra-arterial Chemotherapy With Cisplatin and Mitomycin-C in Patients With Hepatocellular Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatocellular Carcinoma", "Liver Cancer" ], "interventions": [ { "name": "mitomycin-c, cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 76, "start_date": "2004-10-18", "completion_date": "2023-03-06", "has_results": true, "last_update_posted_date": "2025-10-30", "last_synced_at": "2026-10-18T12:17:18.313Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00183885" }, { "nct_id": "NCT03680508", "title": "TSR-022 (Anti-TIM-3 Antibody) and TSR-042 (Anti-PD-1 Antibody) in Patients With Liver Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adult Primary Liver Cancer", "Advanced Adult Primary Liver Cancer", "Localized Unresectable Adult Primary Liver Cancer" ], "interventions": [ { "name": "TSR-022 and TSR-042", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Hawaii", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2019-12-19", "completion_date": "2027-10", "has_results": false, "last_update_posted_date": "2026-04-02", "last_synced_at": "2026-10-18T12:17:18.313Z", "location_count": 2, "location_summary": "Honolulu, Hawaii • Portland, Oregon", "locations": [ { "city": "Honolulu", "state": "Hawaii" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT03680508" }, { "nct_id": "NCT05458791", "title": "Intra-arterial Perfusion in Interventional Radiology", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Hepatocellular Carcinoma" ], "interventions": [ { "name": "Intra-arterial Perfusion", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Palo Alto Veterans Institute for Research", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2022-07-01", "completion_date": "2024-01", "has_results": false, "last_update_posted_date": "2022-07-19", "last_synced_at": "2026-10-18T12:17:18.313Z", "location_count": 1, "location_summary": "Palo Alto, California", "locations": [ { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05458791" }, { "nct_id": "NCT07285044", "title": "The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Amyloidosis", "Basal Cell Carcinoma", "Biliary Tract Carcinoma", "Bladder Carcinoma", "Breast Carcinoma", "Cervical Carcinoma", "Colorectal Carcinoma", "Endometrial Carcinoma", "Fallopian Tube Carcinoma", "Gastroesophageal Junction Carcinoma", "Glioblastoma", "Head and Neck Carcinoma", "Hematopoietic and Lymphatic System Neoplasm", "Hepatocellular Carcinoma", "Hodgkin Lymphoma", "Lung Carcinoma", "Malignant Solid Neoplasm", "Mantle Cell Lymphoma", "Melanoma", "Merkel Cell Carcinoma", "Multiple Myeloma", "Myelodysplastic Syndrome", "Ovarian Carcinoma", "Pancreatic Carcinoma", "Primary Peritoneal Carcinoma", "Prostate Carcinoma", "Renal Cell Carcinoma", "Squamous Cell Carcinoma", "Urothelial Carcinoma" ], "interventions": [ { "name": "Cancer Therapeutic Procedure", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2025-12-18", "completion_date": "2027-05-15", "has_results": false, "last_update_posted_date": "2026-09-30", "last_synced_at": "2026-10-18T12:17:18.313Z", "location_count": 1, "location_summary": "Jacksonville, Florida", "locations": [ { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07285044" }, { "nct_id": "NCT02586987", "title": "A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lung Cancer", "Melanoma", "Head and Neck Carcinoma", "Gastroesophageal Cancer", "Breast Cancer", "Pancreatic Adenocarcinoma", "Colorectal Cancer", "Biliary Tract Cancer" ], "interventions": [ { "name": "Selumetinib", "type": "DRUG" }, { "name": "MEDI4736", "type": "DRUG" }, { "name": "Tremelimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 58, "start_date": "2015-12-28", "completion_date": "2019-09-20", "has_results": false, "last_update_posted_date": "2019-11-18", "last_synced_at": "2026-10-18T12:17:18.313Z", "location_count": 6, "location_summary": "Chicago, Illinois • Boston, Massachusetts • Las Vegas, Nevada + 3 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "Charlotte", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02586987" }, { "nct_id": "NCT04929015", "title": "Peritoneal Carcinomatosis Leveraging ctDNA Guided Treatment in GI Cancer Study (PERICLES Study)", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Appendix Carcinoma by AJCC V8 Stage", "Colorectal Carcinoma by AJCC V8 Stage", "Digestive System Neoplasm", "Esophageal Carcinoma by AJCC V8 Stage", "Gastric Carcinoma by AJCC V8 Stage", "Liver and Intrahepatic Bile Duct Carcinoma", "Peritoneal Carcinomatosis" ], "interventions": [ { "name": "Biospecimen Collection - blood and tissue sample collection", "type": "PROCEDURE" }, { "name": "Electronic Health Record Review", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "OTHER" ], "sponsor": "Rutgers, The State University of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2021-04-29", "completion_date": "2027-09-01", "has_results": false, "last_update_posted_date": "2026-05-04", "last_synced_at": "2026-10-18T12:17:18.313Z", "location_count": 2, "location_summary": "Livingston, New Jersey • New Brunswick, New Jersey", "locations": [ { "city": "Livingston", "state": "New Jersey" }, { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT04929015" }, { "nct_id": "NCT00021047", "title": "Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Esophageal Cancer", "Extrahepatic Bile Duct Cancer", "Gastric Cancer", "Head and Neck Cancer", "Liver Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "capecitabine", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "epirubicin hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institutes of Health Clinical Center (CC)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2001-07", "completion_date": "2004-06", "has_results": false, "last_update_posted_date": "2012-03-08", "last_synced_at": "2026-10-18T12:17:18.313Z", "location_count": 3, "location_summary": "Bethesda, Maryland • Portsmouth, Virginia", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Portsmouth", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00021047" }, { "nct_id": "NCT03439085", "title": "DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Human Papillomavirus-16 Positive", "Human Papillomavirus-18 Positive", "Metastatic Malignant Neoplasm", "Recurrent Anal Canal Carcinoma", "Recurrent Cervical Carcinoma", "Recurrent Malignant Neoplasm", "Recurrent Penile Carcinoma", "Recurrent Vaginal Carcinoma", "Recurrent Vulvar Carcinoma", "Refractory Malignant Neoplasm", "Stage IV Anal Cancer AJCC v8", "Stage IV Cervical Cancer AJCC v8", "Stage IV Penile Cancer AJCC v8", "Stage IV Vaginal Cancer AJCC v8", "Stage IV Vulvar Cancer AJCC v8", "Stage IVA Cervical Cancer AJCC v8", "Stage IVA Vaginal Cancer AJCC v8", "Stage IVA Vulvar Cancer AJCC v8", "Stage IVB Cervical Cancer AJCC v8", "Stage IVB Vaginal Cancer AJCC v8", "Stage IVB Vulvar Cancer AJCC v8" ], "interventions": [ { "name": "DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457", "type": "BIOLOGICAL" }, { "name": "Durvalumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2018-11-14", "completion_date": "2022-09-20", "has_results": true, "last_update_posted_date": "2024-07-09", "last_synced_at": "2026-10-18T12:17:18.313Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03439085" } ] }